Palantir Technologies faces escalating scrutiny over its role handling sensitive British data, after a coalition of MPs and civil liberties groups labelled the US company's position in the UK's public sector as "unacceptable" without stronger safeguards. The Denver-based firm manages key datasets for the National Health Service and several defence ministries, contracts worth an estimated $1.3 billion over five years. Lawmakers on the Public Administration and Constitutional Affairs Committee warned on Thursday that the arrangement grants an American defence contractor unprecedented access to citizen information with insufficient oversight mechanisms in place.
Lawmakers Escalate Oversight Demands
The parliamentary committee has given the Cabinet Office until the end of January to explain what contractual protections exist preventing Palantir from sharing British public data with US intelligence agencies. Committee chair Sir Bernard Jenkin told Parliament the arrangement "simply cannot continue as it stands" without legally binding guarantees on data sovereignty. The Ministry of Defence declined to confirm whether Palantir systems process classified material for British military operations, citing operational security grounds.
Palantir's London office, opened in 2021, has expanded to 340 employees following wins across NHS England's Foundry platform and the Ministry of Defence's intelligence-sharing infrastructure. The company has previously stated it does not own any data it processes and operates solely as a software provider. Its shares, traded on the New York Stock Exchange, have gained 47 percent this year as government contracts worldwide expanded.
Investor Response and Market Implications
Palantir shares dipped 3.2 percent on Friday following the committee's warning, wiping roughly $900 million from the company's market capitalisation. Analysts at Goldman Sachs noted the Britain controversy comes as Palantir pursues larger EU contracts subject to the bloc's Digital Services Act. Any UK policy shift could influence how Brussels structures its own data governance requirements, the analysts wrote in a client note.
Civil Society Joins the Criticism
Privacy advocacy group Privacy International filed a formal complaint alongside the parliamentary submission, arguing Palantir's architecture allows data patterns to be reconstructed even after nominal anonymisation. The campaign group Open Rights Foundation separately warned that the NHS contract effectively creates a surveillance capability disguised as healthcare analytics. Both organisations pointed to Palantir's history with US Immigration and Customs Enforcement as evidence of how government data partnerships can expand beyond stated purposes.
The controversy extends beyond Parliament. The Information Commissioner's Office confirmed it has received two formal complaints regarding Palantir's NHS work and expects to conclude its preliminary assessment by March. A finding against the NHS could force contract renegotiation mid-term, triggering penalties and potentially destabilising the company's revenue projections for European operations.
Government Defends Existing Safeguards
Cabinet Office minister Alex Norris rejected the characterisation of Palantir's role as unacceptable, telling the committee all data processing complies with UK GDPR requirements. Norris confirmed the government has commissioned an independent legal review of data flows between Palantir systems and any affiliated US entities. He declined to publish the review's terms of reference, citing commercial sensitivity surrounding the contract structure.
The NHS England contract, originally awarded in 2019 under emergency pandemic provisions, became a standing agreement in 2022 despite objections from junior health ministry officials who questioned the value-for-money assessment. Documents released under Freedom of Information show Palantir charged roughly £40 million annually for services that internal audits rated "partially meeting" requirements for two consecutive years.
Technology Sector Rivals Watch Closely
Palantir's difficulties create an opening for competitors including IBM, Accenture, and UK-based Faculty AI, which bid on earlier NHS contracts but lost to the American firm. Sources familiar with procurement discussions say Faculty has held informal talks with NHS England about emergency transition arrangements should the Palantir deal face suspension. Faculty declined to comment on any commercial discussions.
The technology sector globally faces growing pressure on data localisation. Australia passed legislation last year requiring government data to be stored domestically, while France has pushed for similar European Union-wide restrictions on American cloud providers. Britain's response to the Palantir situation will signal whether post-Brexit regulatory philosophy tilts toward deregulation to attract tech investment or toward stricter data sovereignty rules.
What's Next: Deadlines and Parliamentary Timeline
The Cabinet Office faces a January 31 deadline to respond to the committee's demands for contractual documentation and legal analysis of data sharing arrangements. The Public Administration Committee is scheduled to hold a public evidence session in February where Palantir executives are expected to appear, though the company has not confirmed whether its European president will attend in person. Should the committee issue a formal condemnation, it would represent a rare rebuke of an active government technology supplier and could trigger a cross-government procurement review. Investors will watch the February hearing closely for any signals about future contract renewals due in 2025.
He declined to publish the review's terms of reference, citing commercial sensitivity surrounding the contract structure.The NHS England contract, originally awarded in 2019 under emergency pandemic provisions, became a standing agreement in 2022 despite objections from junior health ministry officials who questioned the value-for-money assessment. Sources familiar with procurement discussions say Faculty has held informal talks with NHS England about emergency transition arrangements should the Palantir deal face suspension.
